NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is making strides in the development of obicetrapib, an oral, low-dose, once-daily cholesteryl ester transfer protein (CETP) inhibitor, as a preferred LDL-C lowering therapy. The company has announced positive results from three pivotal Phase 3 trials and outlined its strategic priorities for 2025, emphasizing further clinical data releases and commercial readiness.
Positive Phase 3 Results
In 2024, NewAmsterdam Pharma reported positive topline results from the BROADWAY, TANDEM, and BROOKLYN Phase 3 trials. These trials evaluated obicetrapib as a monotherapy and in a fixed-dose combination with ezetimibe in patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C was not adequately controlled despite being on maximally tolerated lipid-lowering therapy.
The BROADWAY trial, involving 2,530 adult patients, achieved its primary endpoint with a statistically significant LDL-C reduction of 33% (p<0.0001) at day 84 with obicetrapib 10 mg compared to placebo. An exploratory analysis also showed a 21% reduction in major adverse cardiovascular events (MACE) favoring obicetrapib.
The TANDEM trial, which evaluated obicetrapib in a fixed-dose combination with ezetimibe in 407 patients, met all co-primary endpoints, demonstrating a 49% reduction (p < 0.0001) in LDL-C compared to placebo at day 84.
The BROOKLYN trial, with 354 patients with HeFH, met its primary endpoint, achieving a 36% reduction (p < 0.0001) in LDL-C compared to placebo at day 84.
2025 Strategic Priorities
NewAmsterdam Pharma plans to release additional data from its Phase 3 studies, including BROADWAY, TANDEM, and BROOKLYN, throughout 2025. These data are expected to support global regulatory filings for obicetrapib, including an EMA submission in the second half of 2025 by their partner Menarini.
The company is also conducting the Phase 2 VINCENT trial to assess the effects of obicetrapib alone and in combination with evolocumab on lipoprotein(a) (Lp(a)) in patients with mild dyslipidemia. Results from this trial are expected in the second half of 2025.
Additionally, the REMBRANDT trial, a Phase 3 cardiovascular computed tomography angiography imaging trial, is evaluating the effect of obicetrapib plus ezetimibe FDC on coronary plaque in adult participants with high-risk ASCVD. This study is expected to complete in 2027.
Commercial Readiness
A key focus for NewAmsterdam Pharma in 2025 is commercial manufacturing and readiness. The company plans to scale up and build inventory sufficient for potential U.S. and European launches, supported by approximately $835 million in cash on hand at the end of 2024.
Ongoing PREVAIL Trial
The company's Phase 3 PREVAIL cardiovascular outcomes trial (CVOT) is ongoing, evaluating obicetrapib in patients with a history of ASCVD. Enrollment of over 9,500 patients was completed in April 2024, and the trial is progressing as expected. The PREVAIL trial is designed to assess the potential of obicetrapib to reduce major adverse cardiovascular events (MACE).
According to Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam, 2024 was a landmark year for the company. He noted the positive results from the Phase 3 trials and the potential of obicetrapib to lower LDL-C and address critical cardiovascular risks. Dr. Davidson also emphasized the company's focus on sharing scientific findings and advancing the PREVAIL trial towards a successful data readout.
With a strong financial position, NewAmsterdam Pharma is poised to potentially transform cardiovascular disease care globally, addressing the unmet needs of millions living with dyslipidemia and at heightened risk for CVD.
